What You Should Know:
– AstraZeneca selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment
– Digital health represents a major opportunity to alleviate some of the biggest concerns in healthcare today—many of which are being amplified due to COVID 19—including the length and cost of clinical trials, better remote testing, and tracking of patients, access to data and delivery of care.
– AstraZeneca and others are choosing to partner with BrightInsight to build applications more quickly and at a lower cost rather than build a custom platform from scratch.
BrightInsight, Inc., provider of the leading regulated Internet of Things (IoT) platform for biopharma and medtech, announced today a global digital health partnership with global biopharmaceutical leader, AstraZeneca. AstraZeneca selected the regulated BrightInsight Platform for its growing portfolio of digital health products and services.
Built under a robust Quality Management System to support regulated use cases, the BrightInsight Platform enables its biopharma and medtech customers to develop and host digital health devices, apps, algorithms, and Software as a Medical Device (SaMD) at scale while maintaining compliance with privacy, security and regulatory requirements across the globe.
As part of the partnership, AstraZeneca will develop apps, algorithms, Software as a Medical Device and connected devices on top of the BrightInsight Platform that enhances and personalize care while making overall healthcare delivery more efficient for patients and providers. The first major program the companies are collaborating on is in the chronic disease management space.
“We quickly dismissed the concept of building our own custom platform so we could focus instead on developing transformational digital health solutions that bring to the forefront our deep-rooted history in science and focus on driving patient outcomes,” said Karan Arora, Chief Commercial Digital Officer and Global Vice President, AstraZeneca. “We selected BrightInsight because its pre-built, compliant platform accelerates our time to market while allowing us to focus on digital health innovation and leveraging our clinical know-how to improve patient outcomes instead of the underlying infrastructure.”